[DNA microarrays and prediction of clinical outcome in ovarian carcinoma patients]. / Puces à ADN et prédiction de l'évolution clinique des cancers ovariens.
Bull Cancer
; 97(8): 979-89, 2010 Aug.
Article
en Fr
| MEDLINE
| ID: mdl-20679035
ABSTRACT
Despite debulking surgery and taxane/platinum-based chemotherapy, ovarian cancer is the most lethal pelvic gynaecological cancer in western countries, with a 25% 5-years survival. Current histo-clinical prognostic factors are insufficient to capture the heterogeneous clinical outcome of patients. A better molecular characterization of the disease is crucial to refine the prognostic classifications and to identify new therapeutic targets. DNA microarrays, which allow the quantitative measurement of expression level of the whole genome simultaneously in a single tumor sample, have been recently used towards this objective with promising results. Here, we present and discuss the main published studies and the issues to address in the future to allow the expected transfer to clinical practice.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Ováricas
/
Análisis de Secuencia por Matrices de Oligonucleótidos
Tipo de estudio:
Prognostic_studies
/
Risk_factors_studies
Límite:
Female
/
Humans
Idioma:
Fr
Revista:
Bull Cancer
Año:
2010
Tipo del documento:
Article
País de afiliación:
Francia